You are here


  • Biosimilars Webcasts

    This webcasts platform offers roundtable discussion with experts specializing in breast, lung, hematologic, and gynecologic cancers highlight the scientific rationale behind biosimilarity and extrapolation. They provide practical insight into the implications of biosimilars for clinical practices, including their potential to expand access to important medicines for patients and clinicians.  

  • Treating CD30+ Lymphomas Webcast Platform

    These webcast modules aim to provide education for physicians on the approved brentuximab vedotin data within the licensed indications, and are available to view as separate education modules. The expert faculty, Dr. Anna Sureda and Dr. Martin Hutchings will cover: an introduction to brentuximab vedotin, mode of action, the Phase I and II clinical data for HL and sALCL and the recently released long term survival analysis. Modules also include transplant ineligible patients and safety updates.  

  • Biosimilars Resource Centre

    The Biosimilars Resource Centre is an educational portal that helps healthcare professionals develop their knowledge of biosimilars through e-Learning modules and curated peer-reviewed content. By providing three UEMS-EACCME-accredited e-Learning modules and the latest research, hand-picked by editors, the Resource Centre aims to disseminate knowledge on biosimilars for rheumatologists, gastroenterologists and dermatologists. This freely available resource is hosted by the journal New Horizons in Translational Medicine.

    Each e-Learning module takes 45 minutes to complete and is worth 1 UEMS-EACCME credit. Three expert guest editors act as independent expert reviewers and curate the content of the three e-Learning modules. With downloadable slide decks and new peer-reviewed content added every month, learners will have up-to-date knowledge of the subject.

    After completing the modules, learners will understand the scientific differences between generics and biosimilars, and biosimilars and reference biopharmaceuticals, and know the clinical meaning of these differences. They will also be familiar with the legal aspect of biosimilars approval, and the practical implications for healthcare professionals.